Company news

Elanco Animal Health Incorporated (NYSE:ELAN) news

Every Elanco Animal Health Incorporated press release and news update in one place — announcements, filings coverage, and company updates for investors.

Elanco Animal Health Incorporated (NYSE:ELAN) news

Press releases & updates

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wo...

Elanco Animal Health Reports Second Quarter 2026 Results

Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs

Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolan...

Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement

Elanco To Launch Elanco Ventures With $25 Million Multi-Year Commitment To Accelerate Innovation in Animal Health

Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health

Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs

Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm

New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience

Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Derma...

Elanco Animal Health Reports First Quarter 2026 Results

/C O R R E C T I O N -- Elanco Animal Health/

Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Author...

Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement

Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*

Amlan International and Elanco Collaborate on Japanese Educational Seminars Focused on Calf Health

Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

Elanco Australia Receives APVMA Approval for Advocate™ Ultra Chew: The Broadest Spectrum Parasite Protection* for Dogs in Australia

Elanco to Participate in Upcoming Investor Conferences

Elanco Announces Updates to Board of Directors

Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement

Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Ato...

Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approv...

Elanco Announces Investment in U.S. Manufacturing and R&D, Driven by Tax, Tariff and Regulatory Clarity

Elanco Animal Health Incorporated : Announces Full USDA Approval of CPMA (Now Trutect™) the First-and-Only Treatment for Deadly Canine Pa...

Elanco Investor Day Defines New Era as Sustainable Growth Company

Elanco executive appointed as Neurizon's Board Observer

Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats

Elanco to Participate in the Upcoming Investor Conferences

Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health

Elanco Animal Health Reports Third Quarter 2025 Results

Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotil...

Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs

Elanco to Host Investor Day on December 9

Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement

Elanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-Induced Disease Language

Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbu...

Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education

Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itc...

Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respirator...

Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

Elanco Releases 2024 Impact Report and Introduces New Framework

Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)

Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief